Schwannomatosis Therapeutics Market

SMARCB1-associated schwannomatosis leads the market with a 54.4% share in 2026 by disease type, followed by first-line treatment at 47.8% by treatment setting and pain management therapies at 32.6% by therapy type. Adoption reflects the need for symptom control, while limited treatment options and complex diagnosis remain key constraints.